Dose characterization of the new Bebig IsoSeed® I25.S17 using polymer gel and MRI

A new, molybdenum core, 125I interstitial brachytherapy seed is marketed by Bebig GmbH (IsoSeed® I25.S17) and our group has performed its Dosimetric characterization using Monte Carlo (MC) simulation and Thermoluminescence dosimetry (TLD) as recommended by the AAPM TG-43U1 prior to the clinical implementation of new low-energy seeds. This work presents the results of a supplementary experimental dosimetry study performed using PABIG polymer gel and Magnetic Resonance Imaging (MRI). One new I25.S17 seed and a commercially available, gold core, Bebig IsoSeed® I25.S06 125I seed were positioned at two different locations in a vial filled with water equivalent, PABIG-polymer gel. The gel with the sources in place was MR scanned in 3D at various time intervals after seed placement using a time efficient, 3D, dual echo Turbo Spin Echo pulse sequence. The consensus dosimetry parameters published in the TG-43U1 for the I25.S06 seed were used to derive the gel response calibration curve for each scanning session. The calibration data were then used to provide dosimetry results for the new I25.S17 seed. Experimental results for the new seed in the form of dose distributions as well as dosimetric quantities in the prevalent TG-43 dosimetric formalism were found to be in close agreement with corresponding MC and TLD results. This finding suggests that the polymer gel-MRI method could at least play a supplementary role to TLD dosimetry in the dose characterization of low energy/low dose rate brachytherapy sources, especially in view of its potential for measurements with a fine spatial resolution down to short distances which are inhibitory to conventional experimental techniques.